Comments
Multinational drug-maker GlaxoSmithKline Pharmaceuticals registered a four per cent increase in net profit from ordinary activities, at Rs 152 crore for the three months ended September 30.
This is compared with Rs 145 crore in the corresponding third quarter period last year.
New drugs
The company’s total income was up about 10 per cent in the quarter under review, at Rs 651 crore, as against Rs 716 crore in the same period last year.
During the quarter, the company launched Zimivir for herpes treatment, and expanded its portfolio of central nervous system products by launching Ictacetam used in the treatment of epilepsy.
GSK Pharma Managing Direct Dr Hasit Joshipura said the vaccines business recorded strong growth.
The quarter also saw good growth across verticals, in particular, specialities.
Manufacturing issues
“Sales were impacted by the constraints of sterile manufacture owing to shutdown of one of the suppliers, as well as, on account of constraints at the Nashik facility. These constraints have since been resolved”, he added.
GlaxoSmithKline shares were marginally down on the BSE, at Rs 1996, on Friday.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.